Biotech Values

[DewDiligence]

Re: ABBV-AMGN Humira settlement

The key date is 1/31/23, when ABBV has permitted AMGN to launch Amgevita (Humira FoB) in the US market.

Other Humira-FoB companies such as MNTA will presumably be able to get the same deal, but will they take it?

MNTA’s CEO has asserted that MNTA has a workaround for ABBV’s US Humira patents that pertain to formulation, specifically, which is something that AMGN presumably does not have.

In any case, we probably won’t know for at least a year (when FDA approves MNTA’s M923 Humira FoB) whether MNTA will opt to defend or settle.

p.s. CHRS +3%, MNTA +2% today.